Our metabolic activity data thus suggest that the combination of APR-246 with doxorubicin reduces viability in both TP53-wt and mutant neuroblastoma cell lines, despite the absence of a p53 target gene expression response in the TP53-mutant cell line. The gene discussed is TP53; the disease is neuroblastoma.